drugset / Trial / NCT04456088
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Timeline
- Start
- 2020-07-15
- Primary completion
- 2020-11-15
- Completion
- 2020-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitric Oxide | Other / unclassified | 80 ppm | Inhaled |
| Subject | Nitric Oxide | Other / unclassified | 150 ppm | Inhaled |